In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global (DIDI). The second largest IPO of the year, DiDi (DIDI) upsized and priced at the...read more
Aerovate Therapeutics, which is developing an inhaled formulation of imatinib for pulmonary arterial hypertension (PAH), raised $122 million by offering 8.7 million shares at $14, within the range of $13 to $15. The company originally planned to raise $100...read more
17 IPOs are slated to raise $9.1 billion in the week ahead, led by long-awaited Chinese ride-hailing giant DiDi Global (DIDI).
DiDi (DIDI) plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s...read more
Aerovate Therapeutics, which is developing a dry powder drug formulation for pulmonary arterial hypertension, announced terms for its IPO on Thursday. The Boston, MA-based company plans to raise $100 million by offering 7.2 million shares at a price range...read more
US IPO Weekly Recap: DiDi leads a 19 IPO week, the busiest since 2004
In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global (DIDI). The second largest IPO of the year, DiDi (DIDI) upsized and priced at the...read more
PAH drug developer Aerovate Therapeutics prices upsized IPO at $14 midpoint
Aerovate Therapeutics, which is developing an inhaled formulation of imatinib for pulmonary arterial hypertension (PAH), raised $122 million by offering 8.7 million shares at $14, within the range of $13 to $15. The company originally planned to raise $100...read more
US IPO Week Ahead: DiDi makes its billion-dollar debut in a 17 IPO week
17 IPOs are slated to raise $9.1 billion in the week ahead, led by long-awaited Chinese ride-hailing giant DiDi Global (DIDI). DiDi (DIDI) plans to raise $3.9 billion at a $67.5 billion market cap. DiDi is China’s...read more
Drug formulation developer Aerovate Therapeutics sets terms for $100 million IPO
Aerovate Therapeutics, which is developing a dry powder drug formulation for pulmonary arterial hypertension, announced terms for its IPO on Thursday. The Boston, MA-based company plans to raise $100 million by offering 7.2 million shares at a price range...read more